Merck & Co., Inc. (MRK ... Co. for an investigational oral drug for heart disease called HRS-5346. Under the agreement, Merck will have the exclusive rights to develop, manufacture, and ...

Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug ... a Moderate Buy based on 11 Buys ...

that was reportedly also involved in negotiations to buy out the company. If approved, it would become a companion to Merck's Bayer-partnered heart failure drug Verquvo (vericiguat), cleared by ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around ...

including 64 million people in the U.S. Merck buys rights to heart disease drug in latest China deal Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui ...

Germany’s Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. The German life ...

For example, Merck signed a deal to license a potential blockbuster heart disease drug from its Chinese peer ... the 10 best stocks for investors to buy now… and Merck wasn’t one of them.

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer ...